{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T15:28:17Z","timestamp":1784474897672,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00280-021-04292-4","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T11:02:58Z","timestamp":1621594978000},"page":"369-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants"],"prefix":"10.1007","volume":"88","clinical-trial-number":[{"clinical-trial-number":"nct03983239","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4264-8927","authenticated-orcid":false,"given":"Ken","family":"Ogasawara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanelle","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sekhar","family":"Surapaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas N.","family":"Carayannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Palmisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"issue":"1","key":"4292_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2050-7771-1-5","volume":"1","author":"M Furqan","year":"2013","unstructured":"Furqan M, Mukhi N, Lee B, Liu D (2013) Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res 1(1):5. https:\/\/doi.org\/10.1186\/2050-7771-1-5","journal-title":"Biomark Res"},{"issue":"1","key":"4292_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz DM, Bonelli M, Gadina M, O\u2019Shea JJ (2016) Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 12(1):25\u201336. https:\/\/doi.org\/10.1038\/nrrheum.2015.167","journal-title":"Nat Rev Rheumatol"},{"issue":"21","key":"4292_CR3","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/onc.2012.347","volume":"32","author":"W Vainchenker","year":"2013","unstructured":"Vainchenker W, Constantinescu SN (2013) JAK\/STAT signaling in hematological malignancies. Oncogene 32(21):2601\u20132613. https:\/\/doi.org\/10.1038\/onc.2012.347","journal-title":"Oncogene"},{"key":"4292_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.12688\/f1000research.13167.1","volume":"7","author":"W Vainchenker","year":"2018","unstructured":"Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN (2018) JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Res 7:82. https:\/\/doi.org\/10.12688\/f1000research.13167.1","journal-title":"F1000Res"},{"key":"4292_CR5","unstructured":"(2019) Inrebic (fedratinib) product information. Celgene Corporation"},{"issue":"2","key":"4292_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00280-020-04121-0","volume":"86","author":"K Ogasawara","year":"2020","unstructured":"Ogasawara K, Xu C, Kanamaluru V, Siebers N, Surapaneni S, Ridoux L, Palmisano M, Krishna G (2020) Excretion balance and pharmacokinetics following a single oral dose of [(14)C]-fedratinib in healthy subjects. Cancer Chemother Pharmacol 86(2):307\u2013314. https:\/\/doi.org\/10.1007\/s00280-020-04121-0","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"4292_CR7","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00280-020-04067-3","volume":"85","author":"K Ogasawara","year":"2020","unstructured":"Ogasawara K, Xu C, Kanamaluru V, Palmisano M, Krishna G (2020) Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects. Cancer Chemother Pharmacol 85(5):899\u2013906. https:\/\/doi.org\/10.1007\/s00280-020-04067-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"4292_CR8","unstructured":"US Food and Drug Administration (2020) Clinical drug interaction studies\u2014study design, data analysis, and clinical implications, guidance for industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions. Accessed 17 Aug 2020"},{"key":"4292_CR9","unstructured":"US Food and Drug Administration (2020) Drug development and drug interactions: table of substrates, inhibitors and inducers. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table3-3. Accessed 27 Aug 2020"},{"issue":"9","key":"4292_CR10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","volume":"42","author":"M Niemi","year":"2003","unstructured":"Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivist\u00f6 KT (2003) Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 42(9):819\u2013850. https:\/\/doi.org\/10.2165\/00003088-200342090-00003","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"4292_CR11","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1124\/dmd.111.038067","volume":"39","author":"Y Xu","year":"2011","unstructured":"Xu Y, Zhou Y, Hayashi M, Shou M, Skiles GL (2011) Simulation of clinical drug\u2013drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs. Drug Metab Dispos 39(7):1139\u20131148. https:\/\/doi.org\/10.1124\/dmd.111.038067","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"4292_CR12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/clpt.2010.271","volume":"89","author":"ML Reitman","year":"2011","unstructured":"Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, Stone JA, Ding Y, Witter R, Gibson C, Roupe K, Evers R, Wagner JA, Stoch A (2011) Rifampin\u2019s acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug\u2013drug interaction trial design. Clin Pharmacol Ther 89(2):234\u2013242. https:\/\/doi.org\/10.1038\/clpt.2010.271","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"4292_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1067\/mcp.2002.124519","volume":"72","author":"S Mouly","year":"2002","unstructured":"Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, Watkins PB (2002) Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 72(1):1\u20139. https:\/\/doi.org\/10.1067\/mcp.2002.124519","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"4292_CR14","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00280-020-04074-4","volume":"85","author":"K Ogasawara","year":"2020","unstructured":"Ogasawara K, Vince B, Xu C, Zhang M, Palmisano M, Krishna G (2020) A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects. Cancer Chemother Pharmacol 85(5):995\u20131001. https:\/\/doi.org\/10.1007\/s00280-020-04074-4","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4292_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00280-019-03929-9","volume":"84","author":"K Ogasawara","year":"2019","unstructured":"Ogasawara K, Zhou S, Krishna G, Palmisano M, Li Y (2019) Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia. Cancer Chemother Pharmacol 84(4):891\u2013898. https:\/\/doi.org\/10.1007\/s00280-019-03929-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4292_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00280-020-04102-3","volume":"86","author":"K Ogasawara","year":"2020","unstructured":"Ogasawara K, LoRusso PM, Olszanski AJ, Rixe O, Xu C, Yin J, Palmisano M, Krishna G (2020) Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. Cancer Chemother Pharmacol 86(1):87\u201395. https:\/\/doi.org\/10.1007\/s00280-020-04102-3","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"4292_CR17","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","volume":"29","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29(7):789\u2013796. https:\/\/doi.org\/10.1200\/JCO.2010.32.8021","journal-title":"J Clin Oncol"},{"issue":"8","key":"4292_CR18","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1038\/bcj.2015.63","volume":"5","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, Xu C, Cao H, Talpaz M (2015) A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J 5(8):e335. https:\/\/doi.org\/10.1038\/bcj.2015.63","journal-title":"Blood Cancer J"},{"issue":"4","key":"4292_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00280-020-04131-y","volume":"86","author":"F Wu","year":"2020","unstructured":"Wu F, Krishna G, Surapaneni S (2020) Physiologically based pharmacokinetic modeling to assess metabolic drug\u2013drug interaction risks and inform the drug label for fedratinib. Cancer Chemother Pharmacol 86(4):461\u2013473. https:\/\/doi.org\/10.1007\/s00280-020-04131-y","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4292_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40262-015-0330-y","volume":"55","author":"C Wagner","year":"2016","unstructured":"Wagner C, Pan Y, Hsu V, Sinha V, Zhao P (2016) Predicting the effect of CYP3A inducers on the pharmacokinetics of substrate drugs using physiologically based pharmacokinetic (PBPK) modeling: an analysis of PBPK submissions to the US FDA. Clin Pharmacokinet 55(4):475\u2013483. https:\/\/doi.org\/10.1007\/s40262-015-0330-y","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"4292_CR21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40262-020-00867-1","volume":"59","author":"M Elmeliegy","year":"2020","unstructured":"Elmeliegy M, Vourvahis M, Guo C, Wang DD (2020) Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug\u2013drug interaction studies. Clin Pharmacokinet 59(6):699\u2013714. https:\/\/doi.org\/10.1007\/s40262-020-00867-1","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"4292_CR22","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1124\/dmd.116.070011","volume":"44","author":"J Takano","year":"2016","unstructured":"Takano J, Maeda K, Bolger MB, Sugiyama Y (2016) The prediction of the relative importance of CYP3A\/P-glycoprotein to the nonlinear intestinal absorption of drugs by advanced compartmental absorption and transit model. Drug Metab Dispos 44(11):1808\u20131818. https:\/\/doi.org\/10.1124\/dmd.116.070011","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"4292_CR23","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/clpt.2011.255","volume":"91","author":"S Oswald","year":"2012","unstructured":"Oswald S, Meyer zu Schwabedissen HE, Nassif A, Modess C, Desta Z, Ogburn ET, Mostertz J, Keiser M, Jia J, Hubeny A, Ulrich A, Runge D, Marinova M, L\u00f6tjohann D, Kroemer HK, Siegmund W (2012) Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers. Clin Pharmacol Ther 91(3):506\u2013513. https:\/\/doi.org\/10.1038\/clpt.2011.255","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"4292_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1177\/0091270011405663","volume":"52","author":"JG Shi","year":"2012","unstructured":"Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y, Landman RR, McKeever EG Jr, Punwani NG, Williams WV, Yeleswaram S (2012) The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol 52(6):809\u2013818. https:\/\/doi.org\/10.1177\/0091270011405663","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"4292_CR25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/bcp.12496","volume":"79","author":"YL Teo","year":"2015","unstructured":"Teo YL, Ho HK, Chan A (2015) Metabolism-related pharmacokinetic drug\u2013drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol 79(2):241\u2013253. https:\/\/doi.org\/10.1111\/bcp.12496","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"4292_CR26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/jcph.218","volume":"54","author":"M Zhang","year":"2014","unstructured":"Zhang M, Xu CR, Shamiyeh E, Liu F, Yin JY, von Moltke LL, Smith WB (2014) A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers. J Clin Pharmacol 54(4):415\u2013421. https:\/\/doi.org\/10.1002\/jcph.218","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"4292_CR27","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ajh.25777","volume":"95","author":"CN Harrison","year":"2020","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian J-J, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Shen J, Berry T, Brownstein C, Mesa RA (2020) Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol 95(6):594\u2013603. https:\/\/doi.org\/10.1002\/ajh.25777","journal-title":"Am J Hematol"},{"issue":"5","key":"4292_CR28","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A (2015) Safety andand efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol 1(5):643\u2013651. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1590","journal-title":"JAMA Oncol"},{"issue":"4","key":"4292_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cpdd.161","volume":"4","author":"M Zhang","year":"2015","unstructured":"Zhang M, Xu C, Ma L, Shamiyeh E, Yin J, von Moltke LL, Smith WB (2015) Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): results from two phase I studies in healthy volunteers. Clin Pharmacol Drug Dev 4(4):315\u2013321. https:\/\/doi.org\/10.1002\/cpdd.161","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"4292_CR30","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00280-020-04084-2","volume":"85","author":"K Ogasawara","year":"2020","unstructured":"Ogasawara K, Smith WB, Xu C, Yin J, Palmisano M, Krishna G (2020) Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment. Cancer Chemother Pharmacol 85(6):1109\u20131117. https:\/\/doi.org\/10.1007\/s00280-020-04084-2","journal-title":"Cancer Chemother Pharmacol"},{"key":"4292_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1850.10.1002\/cpdd.850","author":"K Ogasawara","year":"2020","unstructured":"Ogasawara K, Xu C, Yin J, Darpo B, Carayannopoulos L, Xue H, Palmisano M, Krishna G (2020) Evaluation of the potential for QTc prolongation with repeated oral doses of fedratinib in patients with advanced solid tumors. Clin Pharmacol Drug Dev. https:\/\/doi.org\/10.1002\/cpdd.1850.10.1002\/cpdd.850","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04292-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04292-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04292-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T10:12:27Z","timestamp":1628590347000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04292-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["4292"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04292-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"5 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KO, MT, LL, ML, YX, SS, LNC, SZ, MP, and GK are employees of and hold equity ownership in Bristol Myers Squibb. JK is an employee of Covance.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All study procedures were in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent to participate was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors consented to submit the manuscript for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}